Background: Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late‐
stage clinical development for the prevention and treatment of thromboembolic diseases …

For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …

Apixaban is a potent, highly selective, reversible, oral, direct factor Xa (fXa) inhibitor in
development for thrombosis prevention and treatment. The preclinical pharmacokinetic (PK) …

Abstract Apixaban (BMS-562247; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)
phenyl)-4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4-c] pyridine-3-carboxamide), a direct inhibitor …

Dear Sir, Once associated with the thrombus, blood coagulation factor Xa (FXa) still retains
its enzymatic activity, leading to the generation of thrombin and fibrin (1–3). The persistence …

Introduction Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and
treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the …

An ability to readily determine an anticoagulant effect with an emerging class of direct, active
site, oral factor Xa inhibitors is viewed by the medical community as attractive and by some …

Background: Apixaban is an oral, direct factor Xa (FXa) inhibitor in late-stage clinical
development. This study assessed effects of the direct FXa inhibitors, apixaban and …

Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …

Apixaban and other factor Xa (FXa) inhibitors are in late-stage clinical development for
prevention and treatment of thromboembolic diseases. Although routine monitoring will not …